These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15285885)

  • 1. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture.
    Green A; Flynn A; Pedley RB; Dearling J; Begent R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):371-7. PubMed ID: 15285885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
    Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
    Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model.
    Flynn AA; Green AJ; Boxer GM; Casey JL; Pedley RB; Begent RH
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):183-9. PubMed ID: 9989525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
    Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
    Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
    J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor.
    Flynn AA; Green AJ; Pedley RB; Boxer GM; Boden R; Begent RH
    Radiat Res; 2001 Jul; 156(1):28-35. PubMed ID: 11418070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Realistic Multiregion Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical Therapy.
    Vargas CS; Struelens L; D'Huyvetter M; Caveliers V; Covens P
    J Nucl Med; 2023 Mar; 64(3):493-499. PubMed ID: 36229185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney.
    Bouchet LG; Bolch WE; Blanco HP; Wessels BW; Siegel JA; Rajon DA; Clairand I; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1113-47. PubMed ID: 12843230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonuniformity of tumor dose in radioimmunotherapy.
    Humm JL; Cobb LM
    J Nucl Med; 1990 Jan; 31(1):75-83. PubMed ID: 2295944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
    DeNardo GL; Schlom J; Buchsbaum DJ; Meredith RF; O'Donoghue JA; Sgouros G; Humm JL; DeNardo SJ
    Cancer; 2002 Feb; 94(4 Suppl):1332-48. PubMed ID: 11877764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Murine S factors for liver, spleen, and kidney.
    Kolbert KS; Watson T; Matei C; Xu S; Koutcher JA; Sgouros G
    J Nucl Med; 2003 May; 44(5):784-91. PubMed ID: 12732681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with 131iodine-labeled antibody for a colon cancer model.
    Roberson PL; Buchsbaum DJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5811s-5816s. PubMed ID: 7493351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.
    Emfietzoglou D; Kostarelos K; Sgouros G
    J Nucl Med; 2001 Mar; 42(3):499-504. PubMed ID: 11337529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.